A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

NCT01556776 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

89

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: lenalidomide
DRUG: Placebo

Sponsor

German CLL Study Group

Collaborators

[object Object]